Usless c**** that can't do basic forecasting right. Corporate and process governance is highly questionable and credibitly is zero.

IME announced first deal to drive US market expansion today. Trial for now, full contract subject to FDA clearnace and successfully tweaking to US market. Should this go to plan, likely to get full scope of work from Rad One which increases TCV by 10%+. Good way to get a foot in the door and prep for the US market. I also note the CEO and company have been more active in attending and participating in US tradeshows as initial marketing momentum is being built up.

Baby version of PME. has RIS/PACs software for radiology departments. Main focus is Latam markets but plans to broaden out. Latam market is huge with lazy incumbents who are at risk of losing market share to more nimble, speciliast providers like IME.

Signed a funding facility for $2m today which covers the working capital shortfall experienced as they signed more PaaS deals that need more upfront spending. Should be in a position to capitalise on the heavily discounts sales pipeline of $41m as detailed in the FY18 result call the other month (link below). 

http://www.openbriefing.com/OB/IMEXHS-Limited/2019/3/5/IMEXHS-Limited-FY18-Full-Year-Results-Investor-Conference-Call-/3283.aspx

Big volume rally on news of the company signing its largest contract yet. The operating leverage from tech/business model like this will be huge. Given small base, most contracts will add big revenues and profits. Likely the first of many decent deals ahead of the company, ideally a few more of this size. TCV up over 20% since listing and SP has barely risen twice that proportion, still heavily undervalued to peers.

https://www.asx.com.au/asxpdf/20181022/pdf/43zgr1lg60hsq0.pdf